Barclays’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $87.6K | Sell |
72,996
-235,546
| -76% | -$287K | ﹤0.01% | 4084 |
|
|
2025
Q4 | $303K | Buy |
308,542
+98,055
| +47% | +$118K | ﹤0.01% | 4121 |
|
|
2025
Q3 | $265K | Sell |
210,487
-242,585
| -54% | -$262K | ﹤0.01% | 4166 |
|
|
2025
Q2 | $507K | Buy |
453,072
+85,787
| +23% | +$99.7K | ﹤0.01% | 3756 |
|
|
2025
Q1 | $290K | Sell |
367,285
-49,446
| -12% | -$60.6K | ﹤0.01% | 3851 |
|
|
2024
Q4 | $688K | Sell |
416,731
-7,546
| -2% | -$19K | ﹤0.01% | 3631 |
|
|
2024
Q3 | $1.48M | Buy |
424,277
+301,389
| +245% | +$1.17M | ﹤0.01% | 3092 |
|
|
2024
Q2 | $403K | Sell |
122,888
-201,355
| -62% | -$881K | ﹤0.01% | 3178 |
|
|
2024
Q1 | $2.38M | Sell |
324,243
-35,132
| -10% | -$217K | ﹤0.01% | 2427 |
|
|
2023
Q4 | $1.34M | Buy |
359,375
+240,624
| +203% | +$568K | ﹤0.01% | 3220 |
|
|
2023
Q3 | $252K | Sell |
118,751
-360,348
| -75% | -$1.19M | ﹤0.01% | 3191 |
|
|
2023
Q2 | $2.28M | Sell |
479,099
-21,723
| -4% | -$120K | ﹤0.01% | 1809 |
|
|
2023
Q1 | $2.85M | Buy |
500,822
+236,947
| +90% | +$1.43M | ﹤0.01% | 1929 |
|
|
2022
Q4 | $2.66M | Buy |
263,875
+84,960
| +47% | +$1.6M | ﹤0.01% | 2052 |
|
|
2022
Q3 | $4.01M | Buy |
178,915
+158,098
| +759% | +$4.57M | ﹤0.01% | 1300 |
|
|
2022
Q2 | $516K | Sell |
20,817
-581
| -3% | -$16K | ﹤0.01% | 2818 |
|
|
2022
Q1 | $830K | Sell |
21,398
-84,820
| -80% | -$3.28M | ﹤0.01% | 2546 |
|
|
2021
Q4 | $6.21M | Buy |
106,218
+51,470
| +94% | +$2.92M | ﹤0.01% | 1558 |
|
|
2021
Q3 | $3.24M | Buy |
54,748
+12,204
| +29% | +$957K | ﹤0.01% | 1951 |
|
|
2021
Q2 | $3.69M | Sell |
42,544
-67,235
| -61% | -$5.42M | ﹤0.01% | 1775 |
|
|
2021
Q1 | $9.05M | Sell |
109,779
-20,070
| -15% | -$1.92M | ﹤0.01% | 1137 |
|
|
2020
Q4 | $11.8M | Sell |
129,849
-29,142
| -18% | -$1.81M | 0.01% | 1090 |
|
|
2020
Q3 | $6.36M | Buy |
158,991
+22,337
| +16% | +$780K | ﹤0.01% | 1266 |
|
|
2020
Q2 | $4.69M | Buy |
136,654
+27,082
| +25% | +$807K | ﹤0.01% | 1424 |
|
|
2020
Q1 | $2.43M | Buy |
109,572
+48,919
| +81% | +$1.24M | ﹤0.01% | 2104 |
|
|
2019
Q4 | $1.19M | Buy |
60,653
+5,468
| +10% | +$86.8K | ﹤0.01% | 3525 |
|
|
2019
Q3 | $858K | Sell |
55,185
-21,327
| -28% | -$409K | ﹤0.01% | 3801 |
|
|
2019
Q2 | $1.55M | Buy |
76,512
+43,706
| +133% | +$788K | ﹤0.01% | 3203 |
|
|
2019
Q1 | $576K | Buy |
32,806
+347
| +1% | +$5.48K | ﹤0.01% | 3979 |
|
|
2018
Q4 | $416K | Sell |
32,459
-1,068
| -3% | -$14.9K | ﹤0.01% | 3970 |
|
|
2018
Q3 | $547K | Buy |
33,527
+26,085
| +351% | +$308K | ﹤0.01% | 4196 |
|
|
2018
Q2 | $85K | Sell |
7,442
-11,363
| -60% | -$125K | ﹤0.01% | 5345 |
|
|
2018
Q1 | $184K | Buy |
18,805
+12,577
| +202% | +$120K | ﹤0.01% | 4900 |
|
|
2017
Q4 | $38K | Buy |
6,228
+3,545
| +132% | +$15.8K | ﹤0.01% | 5911 |
|
|
2017
Q3 | $11K | Sell |
2,683
-8,985
| -77% | -$30.6K | ﹤0.01% | 6083 |
|
|
2017
Q2 | $38K | Sell |
11,668
-13,475
| -54% | -$51.6K | ﹤0.01% | 5495 |
|
|
2017
Q1 | $115K | Buy |
+25,143
| New | +$92K | ﹤0.01% | 4783 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Barclays's FATE Position: Q1 2026 in Review
Barclays reduced its Fate Therapeutics (FATE) stake by 76% in Q1 2026, selling an estimated $287K and leaving 72,996 shares worth $87.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4084.
Barclays first reported a position in FATE in Q1 2017 and has held it in 37 quarters since. The position peaked at $11.8M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Barclays held 72,996 shares of Fate Therapeutics worth $87.6K as of Q1 2026.
- Barclays sold 235,546 Fate Therapeutics shares in Q1 2026, an estimated $287K.
- Fate Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4084 holding.
- Barclays first reported a position in Fate Therapeutics in Q1 2017 and has held it in 37 quarters since.
- Barclays's Fate Therapeutics position peaked at $11.8M in Q4 2020.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.